This phenomenon is supported by an MDACC trial, which explored the clinical outcomes associated with pembrolizumab administration (200 mg every 3 weeks) with or without concurrent radiotherapy (SBRT 50 Gy in 4 fractions or traditionally fractionated radiotherapy 45Gy in 15 fractions) regardless of tumor PD-L1 expression in 100 patients with metastatic NSCLC. The gene discussed is CD274; the disease is neoplasm.